Immix Biopharma - Full steam ahead with US CAR-T trial
Immix Biopharma’s second quarter was headlined by intensified clinical activity for lead CAR-T asset NXC-201 (targeting amyloid light chain...
184 Views
Immix Biopharma - US$8m grant to advance novel CAR-T treatment
Immix Biopharma has received a grant of US$8m from the California Institute for Regenerative Medicine (CIRM) to advance clinical development of its...
242 Views
Immix Biopharma - US CAR-T trial commences patient dosing
Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead...
195 Views
Immix Biopharma - All roads lead to NEXICART-2
Immix Biopharma’s Q124 report reflected a period focused on its lead CAR-T asset, NXC-201, targeting amyloid light chain amyloidosis (ALA), which...
206 Views
Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T
Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with...
289 Views